CNS Pharmaceuticals, Inc. Research And Development Expense

Quick Answer

CNS Pharmaceuticals, Inc. reported Research And Development Expense of $9.77 million for the year ending 2025.

  • CNS Pharmaceuticals, Inc. showed an increase of +5.2% in Research And Development Expense from 2024 to 2025.
  • This data is from CNS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
  • XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2018 to 2025), CNS Pharmaceuticals, Inc.'s Research And Development Expense has grown by 45,848.8%.
  • Historical annual values: Fiscal year 2025: $9.77 million | Fiscal year 2024: $9.29 million | Fiscal year 2023: $14.10 million | Fiscal year 2022: $9.30 million | Fiscal year 2021: $9.81 million | Fiscal year 2020: $5.06 million | Fiscal year 2019: $1.85 million | Fiscal year 2018: $21.3 thousand.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: